MX2020010130A - Formulacion y metodo de preparacion. - Google Patents
Formulacion y metodo de preparacion.Info
- Publication number
- MX2020010130A MX2020010130A MX2020010130A MX2020010130A MX2020010130A MX 2020010130 A MX2020010130 A MX 2020010130A MX 2020010130 A MX2020010130 A MX 2020010130A MX 2020010130 A MX2020010130 A MX 2020010130A MX 2020010130 A MX2020010130 A MX 2020010130A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- formulations
- pharmaceutical composition
- formulation
- monitoring
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 3
- 238000012544 monitoring process Methods 0.000 abstract 3
- 238000003384 imaging method Methods 0.000 abstract 2
- 206010061818 Disease progression Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 239000013022 formulation composition Substances 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen formulaciones para administración humana o animal y a un método de preparación de las mismas. En particular, se describen formulaciones farmacéuticas más estables, tal como aquellas para la administración intravenosa, y a un método de preparación de las mismas. También se describen formulaciones liofilizadas que tiene un ingrediente farmacéutico activo (API), un agente amortiguador y un lioprotector, en donde el API es un agente formador de imágenes que comprende al menos un péptido de unión a cMet, adecuado para formar en imágenes ópticamente el cuerpo de mamífero in vivo. También se describen un método para preparar una formulación liofilizada, una composición farmacéutica, y un kit para la preparación de la composición farmacéutica. Se describen además métodos de formación de imágenes usando la formulación o composición farmacéutica, tal como en la detección, diagnóstico, cirugía, estadificación, tratamiento, vigilancia del tratamiento, vigilancia de la progresión de la enfermedad o vigilancia de la terapia de las afecciones tal como cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1804835.5A GB201804835D0 (en) | 2018-03-26 | 2018-03-26 | Formulation and method of preparation |
| PCT/EP2019/057538 WO2019185607A1 (en) | 2018-03-26 | 2019-03-26 | Formulation and method of preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010130A true MX2020010130A (es) | 2021-01-08 |
Family
ID=62068063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010130A MX2020010130A (es) | 2018-03-26 | 2019-03-26 | Formulacion y metodo de preparacion. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20210046195A1 (es) |
| EP (1) | EP3773750B1 (es) |
| JP (2) | JP2021519300A (es) |
| KR (1) | KR20200136007A (es) |
| CN (1) | CN112203698A (es) |
| AU (1) | AU2019246196A1 (es) |
| BR (1) | BR112020019367A2 (es) |
| CA (1) | CA3094571A1 (es) |
| DK (1) | DK3773750T3 (es) |
| ES (1) | ES2923148T3 (es) |
| GB (1) | GB201804835D0 (es) |
| HR (1) | HRP20220850T1 (es) |
| HU (1) | HUE059216T2 (es) |
| LT (1) | LT3773750T (es) |
| MX (1) | MX2020010130A (es) |
| PL (1) | PL3773750T3 (es) |
| PT (1) | PT3773750T (es) |
| RS (1) | RS63388B1 (es) |
| SG (1) | SG11202009315WA (es) |
| SI (1) | SI3773750T1 (es) |
| WO (1) | WO2019185607A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11709156B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved analytical analysis |
| US11709155B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes |
| US11918936B2 (en) | 2020-01-17 | 2024-03-05 | Waters Technologies Corporation | Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding |
| WO2023095887A1 (ja) * | 2021-11-26 | 2023-06-01 | アステラス製薬株式会社 | インドシアニン化合物含有固形医薬組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1046516C (zh) * | 1994-04-25 | 1999-11-17 | 协和发酵工业株式会社 | 化合物dx－52－1的稳定方法和其冻干组合物 |
| CA2517939C (en) * | 2003-03-03 | 2015-11-24 | Dyax Corp. | Peptides that specifically bind hgf receptor (cmet) and uses thereof |
| JO3324B1 (ar) * | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
| RU2473361C9 (ru) * | 2007-05-16 | 2013-06-20 | ДжиИ Хелткер АС | Меченые пептиды, связывающие фактор роста гепатоцитов (hgf), для визуализации |
| EP2030644A1 (en) * | 2007-08-31 | 2009-03-04 | PARI Pharma GmbH | Aerosols for sinunasal drug delivery |
| GB201013808D0 (en) * | 2010-08-18 | 2010-09-29 | Ge Healthcare Ltd | Peptide radiotracer compositions |
| GB201016206D0 (en) * | 2010-09-27 | 2010-11-10 | Ge Healthcare Ltd | Apoptosis imaging agents |
| GB201020314D0 (en) * | 2010-12-01 | 2011-01-12 | Ge Healthcare Ltd | Apoptosis pet imaging agents |
| GB201103696D0 (en) * | 2011-03-04 | 2011-04-20 | Ge Healthcare Ltd | Technetium labelled peptides |
| GB201314936D0 (en) * | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
| WO2015071299A2 (en) * | 2013-11-12 | 2015-05-21 | Galenicum Health S.L. | Stable pharmaceutical compositions |
| GB201322456D0 (en) * | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
-
2018
- 2018-03-26 GB GBGB1804835.5A patent/GB201804835D0/en not_active Ceased
-
2019
- 2019-03-26 PT PT197134679T patent/PT3773750T/pt unknown
- 2019-03-26 WO PCT/EP2019/057538 patent/WO2019185607A1/en active Search and Examination
- 2019-03-26 BR BR112020019367-4A patent/BR112020019367A2/pt unknown
- 2019-03-26 US US17/041,759 patent/US20210046195A1/en active Pending
- 2019-03-26 HU HUE19713467A patent/HUE059216T2/hu unknown
- 2019-03-26 DK DK19713467.9T patent/DK3773750T3/da active
- 2019-03-26 ES ES19713467T patent/ES2923148T3/es active Active
- 2019-03-26 MX MX2020010130A patent/MX2020010130A/es unknown
- 2019-03-26 KR KR1020207030557A patent/KR20200136007A/ko unknown
- 2019-03-26 LT LTEPPCT/EP2019/057538T patent/LT3773750T/lt unknown
- 2019-03-26 PL PL19713467.9T patent/PL3773750T3/pl unknown
- 2019-03-26 HR HRP20220850TT patent/HRP20220850T1/hr unknown
- 2019-03-26 CN CN201980035582.8A patent/CN112203698A/zh active Pending
- 2019-03-26 CA CA3094571A patent/CA3094571A1/en active Pending
- 2019-03-26 RS RS20220663A patent/RS63388B1/sr unknown
- 2019-03-26 AU AU2019246196A patent/AU2019246196A1/en active Pending
- 2019-03-26 SI SI201930276T patent/SI3773750T1/sl unknown
- 2019-03-26 JP JP2020551822A patent/JP2021519300A/ja active Pending
- 2019-03-26 EP EP19713467.9A patent/EP3773750B1/en active Active
- 2019-03-26 SG SG11202009315WA patent/SG11202009315WA/en unknown
-
2023
- 2023-12-21 JP JP2023215576A patent/JP2024045106A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2923148T3 (es) | 2022-09-23 |
| PT3773750T (pt) | 2022-07-12 |
| JP2024045106A (ja) | 2024-04-02 |
| GB201804835D0 (en) | 2018-05-09 |
| DK3773750T3 (da) | 2022-07-11 |
| US20210046195A1 (en) | 2021-02-18 |
| HUE059216T2 (hu) | 2022-10-28 |
| AU2019246196A1 (en) | 2020-10-29 |
| SG11202009315WA (en) | 2020-10-29 |
| LT3773750T (lt) | 2022-07-25 |
| CN112203698A (zh) | 2021-01-08 |
| RS63388B1 (sr) | 2022-08-31 |
| JP2021519300A (ja) | 2021-08-10 |
| PL3773750T3 (pl) | 2022-08-08 |
| EP3773750B1 (en) | 2022-04-20 |
| RU2020134801A (ru) | 2022-04-27 |
| WO2019185607A1 (en) | 2019-10-03 |
| SI3773750T1 (sl) | 2022-09-30 |
| HRP20220850T1 (hr) | 2022-10-14 |
| KR20200136007A (ko) | 2020-12-04 |
| BR112020019367A2 (pt) | 2021-02-17 |
| EP3773750A1 (en) | 2021-02-17 |
| CA3094571A1 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010130A (es) | Formulacion y metodo de preparacion. | |
| O'Keefe et al. | Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure | |
| EA201101518A1 (ru) | Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии | |
| WO2009043476A3 (en) | Neuromedin s as a therapeutic agent | |
| WO2009046863A3 (en) | Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent | |
| JP6663351B2 (ja) | 温度感受性ヒドロゲル−コラゲナーゼ製剤 | |
| CN104826094A (zh) | 包含增效比例的干扰素γ和α的稳定的制剂 | |
| GB0814302D0 (en) | Compounds and methods | |
| MX2010004508A (es) | Suministro de agentes activos. | |
| WO2009033755A3 (en) | Use of l-carnosine as a therapeutic agent | |
| WO2019113066A1 (en) | Bacteriophage treatment for acne and biofilms | |
| JP2017507995A5 (es) | ||
| BR112013005673A2 (pt) | uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes | |
| CN111542335A (zh) | 炎症性肠病的治疗药 | |
| WO2009046864A3 (en) | Use of the human pancreatic polypeptide as a therapeutic agent | |
| AU2015275237A1 (en) | Compositions and methods for treating joints | |
| RU2012140379A (ru) | Способы и композиции для повышения срока выживаемости жирового трансплантата | |
| WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| JP6595717B2 (ja) | 骨関節炎治療のための親水化されたスルファサラジンおよびヒアルロン酸を含む組成物およびその製造方法 | |
| Urakov et al. | Cold sodium chloride solution 0.9% and infrared thermography can be an alternative to radiopaque contrast agents in phlebography | |
| MX2023000004A (es) | Formulaciones para promover la hidratacion y metodos de uso de las mismas. | |
| JP2023544310A (ja) | プロバイオティクス成分の使用及びプロバイオティクス成分を含む医薬組成物 | |
| RU2491964C1 (ru) | Способ консервативного лечения эпикондилита плеча | |
| JP2018509398A5 (es) | ||
| RU2676263C1 (ru) | Способ коррекции поражений печени у больных бруцеллезом |